Webinar: An interesting new study at NCI: Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Biliary Tract Carcinoma
Webinar: An interesting new study at NCI: Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Biliary Tract Carcinoma
–
July 22, 2021
CCF Webinar Series
An interesting new study at NCI: Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Biliary Tract Carcinoma
Thursday, July 22, 2021, at 4:00pm (EDT)
Presented by: Cecilia Monge, M.D., M.P.H., FACP.
Dr. Cecilia Monge specializes in first-in-human and early-phase clinical studies of gastrointestinal (GI) malignancies, including liver cancer, biliary tract cancer, colorectal cancer and pancreatic cancer.
Join us to learn about a new clinical trial at the National Cancer Institute.
